To assess the outcomes, including safety and impact on length of stay and cost-effectiveness of using oritavancin for patients with Staphylococcus aureus bacteremia (SAB) who are ineligible for outpatient parenteral antibiotic therapy (OPAT), highlighting the challenges in managing these patients.
Key Findings:
Clinical cure was achieved in 26 out of 27 patients (96%), with one patient lost to follow-up and deemed not clinically evaluable.
89% of patients were alive at the end of the 180-day follow-up period.
89% of patients demonstrated a positive return on investment, avoiding an average of 18 hospital days per patient.
Interpretation:
Oritavancin is a promising and potentially cost-effective alternative for managing SAB in patients who are ineligible for OPAT, with significant implications for clinical practice.
Limitations:
Retrospective design limits the ability to establish causality; this should be noted for readers.
Small sample size may affect the generalizability of the findings; further studies are needed.
Lack of prospective studies to confirm utility in clinical practice.
Conclusion:
Oritavancin shows promise as a suitable treatment for SAB in patients who cannot utilize OPAT, warranting further prospective studies to validate these findings.
